Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets ...
A team at RMIT University in Melbourne say that extremely small metal particles – which they dub ‘nanodots’ – could be ...
DESTINY-Endometrial02 is a phase 3 trial assessing T-DXd as an adjuvant treatment for HER2-expressing endometrial cancer, ...
Dr Ambarish Ghosh, professor at IISc Bangalore explains how targeted nanorobots work against cancer, as well as the ...
AstraZeneca said on Monday that a late‑stage trial testing its blockbuster therapy Imfinzi in combination with its experimental drug ceralasertib failed to improve the overall survival of patients ...
FOX 13 Tampa Bay on MSN
USF researchers develop tumor-targeting cancer treatment already saving pets: Human trials could be next
USF medical engineering professors Dr. Richard Heller and Dr. Mark Jaroszeski have spent more than three decades developing a ...
Datopotamab deruxtecan received FDA approval for HR+/HER2– breast cancer, improving progression-free survival and overall ...
BOSTON & SHENZHEN, China--(BUSINESS WIRE)--Signet Therapeutics, a clinical-stage biotech company leveraging organoid- and AI-driven cancer drug discovery, announced that the U.S. Food and Drug ...
News Medical on MSN
Johns Hopkins Scientists Develop Targeted Therapy for T-Cell Lymphomas and Leukemias
Researchers at the Johns Hopkins Kimmel Cancer Center’s Ludwig Center developed a new treatment that selectively targets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback